{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:48:14Z","timestamp":1790736494708,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15348-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T04:24:04Z","timestamp":1763958244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MEF2C induces intrinsic apoptosis and reverses cisplatin resistance in A2780 ovarian cancer cell line"],"prefix":"10.1186","volume":"25","author":[{"given":"Zahra","family":"Fadavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Javad","family":"Mowla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram M.","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"12","key":"15348_CR1","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s11864-023-01138-4","volume":"24","author":"A Ismail","year":"2023","unstructured":"Ismail A, Choi S, Boussios S. Frontiers of ovarian carcinosarcoma. Curr Treat Options Oncol. 2023;24(12):1667\u201382.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"15348_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"15348_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"15348_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/cells13040345","volume":"13","author":"M Murawski","year":"2024","unstructured":"Murawski M, et al. Complexity of the genetic background of oncogenesis in ovarian cancer\u2014genetic instability and clinical implications. Cells. 2024;13(4):345.","journal-title":"Cells"},{"key":"15348_CR5","doi-asserted-by":"publisher","first-page":"1291602","DOI":"10.3389\/fonc.2023.1291602","volume":"13","author":"W Gan","year":"2023","unstructured":"Gan W, Bian C. The research progress on synchronous endometrial and ovarian carcinoma. Front Oncol. 2023;13:1291602.","journal-title":"Front Oncol"},{"issue":"5","key":"15348_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15348_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer. Oncol Rep. 2022;47(4):1\u201311.","journal-title":"Oncol Rep"},{"key":"15348_CR8","doi-asserted-by":"crossref","unstructured":"Marchetti C, et al. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol. 2021;77:144\u201366.","DOI":"10.1016\/j.semcancer.2021.08.011"},{"issue":"3","key":"15348_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/0929867033368484","volume":"10","author":"M Fuertes","year":"2003","unstructured":"Fuertes M, et al. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257\u201366.","journal-title":"Curr Med Chem"},{"issue":"1","key":"15348_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/biomedicines12010229","volume":"12","author":"J Wilczy\u0144ski","year":"2024","unstructured":"Wilczy\u0144ski J, Paradowska E, Wilczy\u0144ski M. High-grade serous ovarian cancer\u2014a risk factor puzzle and screening fugitive. Biomedicines. 2024;12(1):229.","journal-title":"Biomedicines"},{"key":"15348_CR11","doi-asserted-by":"crossref","unstructured":"Dogan E, et al, Targeting apoptosis to overcome chemotherapy resistance. Exon Publications; 2022. p. 163\u201380.","DOI":"10.36255\/exon-publications.metastasis.chemotherapy-resistance"},{"issue":"3","key":"15348_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318740","volume":"20","author":"H Alizadeh","year":"2025","unstructured":"Alizadeh H, et al. Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian endometrioid carcinoma cell line. PLoS ONE. 2025;20(3):e0318740.","journal-title":"PLoS ONE"},{"key":"15348_CR13","doi-asserted-by":"crossref","unstructured":"Alizadeh H, et al, Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: Mechanisms and therapeutic potential. Eur J Pharmacol. 2024;177220:1\u20131.","DOI":"10.1016\/j.ejphar.2024.177220"},{"issue":"1","key":"15348_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","volume":"24","author":"H Alizadeh","year":"2025","unstructured":"Alizadeh H, et al. A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities. Mol Cancer. 2025;24(1):135.","journal-title":"Mol Cancer"},{"key":"15348_CR15","doi-asserted-by":"crossref","unstructured":"Wu G, et al, ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine. 2021;71:103544.","DOI":"10.1016\/j.ebiom.2021.103558"},{"issue":"2","key":"15348_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.arcmed.2018.04.014","volume":"49","author":"M Lu","year":"2018","unstructured":"Lu M, et al. FOXO3a reverses the cisplatin resistance in ovarian cancer. Arch Med Res. 2018;49(2):84\u20138.","journal-title":"Arch Med Res"},{"issue":"4","key":"15348_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006752","volume":"3","author":"E Di Giorgio","year":"2017","unstructured":"Di Giorgio E, et al. The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness. PLoS Genet. 2017;3(4):e1006752.","journal-title":"PLoS Genet"},{"issue":"31","key":"15348_CR18","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1038\/onc.2014.337","volume":"34","author":"X Bai","year":"2015","unstructured":"Bai X, et al. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt\/\u03b2-catenin signaling. Oncogene. 2015;34(31):4089\u201397.","journal-title":"Oncogene"},{"issue":"3","key":"15348_CR19","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.18632\/oncotarget.6223","volume":"7","author":"JR Pon","year":"2015","unstructured":"Pon JR, Marra MA. MEF2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget. 2015;7(3):2297.","journal-title":"Oncotarget"},{"issue":"3","key":"15348_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jphs.2023.04.009","volume":"152","author":"K Sato","year":"2023","unstructured":"Sato K, et al. Platinum-based anticancer drugs-induced downregulation of myosin heavy chain isoforms in skeletal muscle of mouse. J Pharmacol Sci. 2023;152(3):167\u201377.","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"15348_CR21","first-page":"887","volume":"9","author":"X Li","year":"2019","unstructured":"Li X, et al. Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma. Am J Cancer Res. 2019;9(5):887.","journal-title":"Am J Cancer Res"},{"key":"15348_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216643","volume":"584","author":"Q-N Wu","year":"2024","unstructured":"Wu Q-N, et al. HIPK3 maintains sensitivity to platinum drugs and prevents disease progression in gastric cancer. Cancer Lett. 2024;584:216643.","journal-title":"Cancer Lett"},{"issue":"23","key":"15348_CR23","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.3390\/ijms21239218","volume":"21","author":"J Szenajch","year":"2020","unstructured":"Szenajch J, et al. Transcriptome remodeling in gradual development of inverse resistance between paclitaxel and cisplatin in ovarian cancer cells. Int J Mol Sci. 2020;21(23):9218.","journal-title":"Int J Mol Sci"},{"key":"15348_CR24","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/166044","author":"Y Lin","year":"2024","unstructured":"Lin Y, et al. Tasquinimod enhances the sensitivity of ovarian cancer cells to cisplatin by regulating the Nur77-Bcl-2 apoptotic pathway. Adv Clin Exp Med. 2024. https:\/\/doi.org\/10.17219\/acem\/166044.","journal-title":"Adv Clin Exp Med"},{"issue":"15","key":"15348_CR25","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-12-4560","volume":"73","author":"AJ Wilson","year":"2013","unstructured":"Wilson AJ, et al. TR3 modulates platinum resistance in ovarian cancer. Cancer Res. 2013;73(15):4758\u201369.","journal-title":"Cancer Res"},{"key":"15348_CR26","doi-asserted-by":"publisher","first-page":"096368972092998","DOI":"10.1177\/0963689720929983","volume":"29","author":"C Du","year":"2020","unstructured":"Du C, et al. LncRNA DLX6-AS1 contributes to epithelial\u2013mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p\/paxillin axis. Cell Transplant. 2020;29:0963689720929983.","journal-title":"Cell Transplant"},{"issue":"1","key":"15348_CR27","doi-asserted-by":"publisher","first-page":"21014","DOI":"10.1038\/s41598-021-99555-8","volume":"11","author":"X Zhao","year":"2021","unstructured":"Zhao X, et al. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p\/miR-382-5p\/CELF1 axis. Sci Rep. 2021;11(1):21014.","journal-title":"Sci Rep"},{"issue":"6","key":"15348_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/emmm.201202006","volume":"5","author":"J Park","year":"2013","unstructured":"Park J, Morley TS, Scherer PE. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med. 2013;5(6):935\u201348.","journal-title":"EMBO Mol Med"},{"issue":"9\u201310","key":"15348_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000512621","volume":"106","author":"G Hua","year":"2021","unstructured":"Hua G, et al. LncRNA XIST contributes to cisplatin resistance of lung cancer cells by promoting cellular glycolysis through sponging miR-101-3p. Pharmacol. 2021;106(9\u201310):498\u2013508.","journal-title":"Pharmacol"},{"issue":"4","key":"15348_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/CBM-201740","volume":"30","author":"H Zheng","year":"2021","unstructured":"Zheng H, et al. LncRNA XIST\/miR-137 axis strengthens chemo-resistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer Biomark. 2021;30(4):395\u2013406.","journal-title":"Cancer Biomark"},{"issue":"1","key":"15348_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13048-024-01429-w","volume":"17","author":"X-Y Zhang","year":"2024","unstructured":"Zhang X-Y, et al. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis. J Ovarian Res. 2024;17(1):102.","journal-title":"J Ovarian Res"},{"issue":"6","key":"15348_CR32","doi-asserted-by":"publisher","first-page":"e2874","DOI":"10.1038\/cddis.2017.271","volume":"8","author":"C-M Kuang","year":"2017","unstructured":"Kuang C-M, et al. Bst2 confers cisplatin resistance via NF-\u03baB signaling in nasopharyngeal cancer. Cell Death Dis. 2017;8(6):e2874\u2013e2874.","journal-title":"Cell Death Dis"},{"issue":"7","key":"15348_CR33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-020-0195-6","volume":"28","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, et al. Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt\/\u03b2-catenin signaling pathway. Cancer Gene Ther. 2021;28(7):785\u201398.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"15348_CR34","volume":"18","author":"S Palugulla","year":"2017","unstructured":"Palugulla S, et al. Association of voltage-gated sodium channel genetic polymorphisms with oxaliplatin-induced chronic peripheral neuropathy in south Indian cancer patients. Asian Pac J Cancer Prev. 2017;18(11):3157.","journal-title":"Asian Pac J Cancer Prev"},{"key":"15348_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij S, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11:1\u201311.","journal-title":"Clin Epigenetics"},{"key":"15348_CR36","doi-asserted-by":"crossref","unstructured":"Cummings M, C Freer, and N Orsi. Targeting the tumour microenvironment in platinum-resistant ovarian cancer. In: Semin Cancer Biol. Elsevier; 2021. p. 167\u201381.","DOI":"10.1016\/j.semcancer.2021.02.007"},{"issue":"16","key":"15348_CR37","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1093\/emboj\/19.16.4323","volume":"19","author":"HD Youn","year":"2000","unstructured":"Youn HD, Chatila TA, Liu JO. Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J. 2000;19(16):4323\u201331.","journal-title":"EMBO J"},{"issue":"19","key":"15348_CR38","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1242\/jcs.073643","volume":"123","author":"SB Bratton","year":"2010","unstructured":"Bratton SB, Salvesen GS. Regulation of the Apaf-1\u2013caspase-9 apoptosome. J Cell Sci. 2010;123(19):3209\u201314.","journal-title":"J Cell Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15348-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15348-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15348-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:41:46Z","timestamp":1767073306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15348-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15348"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15348-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics, Consent to Participate, and Consent to Publish declarations: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1934"}}